Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Renal and related cancers, and Cancer Genomics and Diagnostics.
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial
The Potential Revolution of Cancer Treatment with CRISPR Technology
Results from phase 3 study of <sup>89</sup>Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON).
CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study
A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer
“Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma
Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance
Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma
Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma
The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
Immunotherapy for the Treatment of Urothelial Carcinoma
High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer
A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer
Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies
Clear Cell Renal Cell Carcinoma: Discrimination from Other Renal Cell Carcinoma Subtypes and Oncocytoma at Multiphasic Multidetector CT
Prognostic Impact of Preoperative Neutrophil-to-Lymphocyte Ratio in Localized Nonclear Cell Renal Cell Carcinoma
ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—Results and implications for adjuvant clinical trials.
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma